Verteporfin API Manufacturers & Suppliers
Find, compare & contact
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Verteporfin API 129497-78-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Verteporfin. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Verteporfin
- Synonyms:
- Verteporfin , Verteporfina , Verteporfinum
- Cas Number:
- 129497-78-5
- DrugBank number:
- DB00460
- Unique Ingredient Identifier:
- 0X9PA28K43
About Verteporfin
Some technical information about this product: Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
More information such as the structure, indication or toxicity is available on Drugbank, click the ID above.
Verteporfin is a type of Macular degeneration drugs
Macular degeneration drugs belong to a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) specifically designed to treat macular degeneration, a common eye condition that causes vision loss in the central part of the retina. These drugs are essential for managing and slowing down the progression of the disease, offering improved visual outcomes for affected individuals.
Macular degeneration drugs primarily target the underlying mechanisms responsible for the condition. The most common type of drug used for this purpose is anti-vascular endothelial growth factor (anti-VEGF) agents. These drugs work by inhibiting the growth of abnormal blood vessels in the eye, which can leak fluid and cause damage to the macula.
The development of macular degeneration drugs involves rigorous research and clinical trials to ensure their safety and efficacy. These drugs are typically administered through intravitreal injections, directly into the eye, to deliver the medication precisely to the affected area.
Due to the growing prevalence of macular degeneration worldwide, pharmaceutical companies have been investing heavily in the research and development of new drugs and treatment options. The continuous advancements in technology and medical understanding have led to the introduction of novel therapies, including gene therapy and sustained-release drug delivery systems.
The availability of effective macular degeneration drugs is crucial for improving the quality of life for individuals affected by this condition. Early detection, regular eye examinations, and timely treatment with these drugs can help manage the disease, preserving visual function and preventing severe vision loss. It is essential for patients to consult with their healthcare professionals to determine the most appropriate macular degeneration drug based on their specific needs and medical history.
Verteporfin (Macular degeneration drugs), classified under Ophthalmic Agents
Ophthalmic agents belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category specifically designed for ophthalmic applications. These agents are formulated to treat various eye conditions and disorders. Ophthalmic agents encompass a wide range of medications, including eye drops, ointments, gels, and intraocular implants.
These agents are developed to address specific therapeutic needs related to the eyes, such as reducing intraocular pressure in glaucoma, treating inflammation and infection, relieving dryness and itching, and managing allergies. They may also be used to dilate the pupils during diagnostic procedures or surgeries.
Ophthalmic agents are formulated with precise concentrations of active ingredients to ensure efficacy and safety. Common classes of ophthalmic agents include beta-blockers, prostaglandin analogs, carbonic anhydrase inhibitors, corticosteroids, and antihistamines.
When administering ophthalmic agents, it is crucial to follow proper application techniques to ensure optimal drug delivery and minimize side effects. Eye drops, for example, are typically applied as a gentle instillation into the conjunctival sac, while ointments are applied along the lower eyelid.
These pharmaceutical API ophthalmic agents undergo rigorous quality control and regulatory scrutiny to meet industry standards and ensure patient safety. Manufacturers must comply with Good Manufacturing Practices (GMP) and adhere to stringent quality assurance protocols.
Overall, ophthalmic agents play a vital role in the management and treatment of various eye conditions, providing patients with targeted relief and improving ocular health. It is important to consult with a healthcare professional to determine the appropriate ophthalmic agent for individual needs and to receive proper guidance on usage and potential side effects.
